Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

Inclusion Criteria

• •Patients must have a pathologically confirmed diagnosis of DLBCL (including DLBCL not otherwise specified \[NOS\], DLBCL germinal center B-cell \[GCB\] type, DLBCL activated B cell \[ABC\]/non-GCB type, T cell/histiocyte-rich large B cell lymphoma, high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and high-grade B cell lymphoma NOS). NOTE: DLBCL transformed from low-grade lymphoma among treatment-naive patients or patients previously treated with a non-anthracycline containing regimen are permitted
• •Patients may have completed the first cycle of R-CHOP (off study not combined with TAK-659) =\< 21 days prior to the first dose of TAK-659 or plan to receive the first cycle of R-CHOP after registration
• •Patients must have at least one high-risk feature, including:
• •* ABC/non-GCB subtype determined by gene expression profiling or Hans algorithm by immunohistochemistry per treating institution standards
• •* High-intermediate or high-risk group by National Comprehensive Cancer Network - International Prognostic Index (NCCN-IPI) with score \>= 4, at time of diagnosis
• •* MYC gene rearrangement (by \[fluorescent in situ hybridization\] FISH)
• •* MYC overexpression by immunohistochemistry (IHC) (\>= 40%) and BLC2 overexpression by IHC (\>= 50%) or
• •* Previously treated transformed low-grade lymphoma to large B cell lymphoma with prior treatment not including an anthracycline
• •* NOTE: BCL2 and/or BCL6 aberrancy are not required for enrollment, but assessment for rearrangement by FISH and overexpression by IHC are required if there is presence of MYC rearranged by FISH
• •Patients must have measurable disease (defined as \>= 1.5 cm in diameter) with correlated fluorodeoxyglucose (FDG)-avidity on positron emission tomography (PET) scan with Deauville score of 4 or 5 at time of diagnosis
• •Patients must have recovered (i.e., =\< grade 1 toxicity) from the reversible effects of prior anticancer therapy, if applicable
• •Life expectancy of greater than 3 months
• •Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• •Absolute neutrophil count \>= 1000/mcL (within 14 days prior to registration)
• •Platelets \>= 75,000/mcl (NOTE: Patients with bone marrow involvement may be eligible with platelets \>= 50,000) (within 14 days prior to registration)
• •Hemoglobin \>= 8 g/dL (within 14 days prior to registration)
• •* NOTE: Red blood cell (RBC) and platelet transfusion allowed \>= 14 days prior to registration
• •Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) (within 14 days prior to registration)
• •Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 2.5 x institutional ULN (within 14 days prior to registration)
• •Creatinine clearance \>= 60 mL/min either as estimated by the Cockcroft-Gault equation or based on urine collection (12 or 24 hours) (within 14 days prior to registration)
• •Lipase =\< 1.5 x ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis (within 14 days prior to registration)
• •Amylase =\< 1.5 x ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis (within 14 days prior to registration)
• •Patients must have blood pressure =\< grade 1
• •* NOTE: Hypertensive patients are permitted if their blood pressure is controlled to =\< grade 1 by hypertensive medications
• •Female patients must meet at least one of the following criteria:
• •* Are postmenopausal with last menstrual period at least 1 year before registration OR
• •* Are surgically sterile, OR
• •* If they are of childbearing potential
• •* Agree to practice 1 highly effective method of contraception and one additional effective (barrier) method at the same time, from the time of signing the informed consent through 180 days after the last dose of study drug, or
• •* Agree to practice true abstinence, when is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods), withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together
• •* Agree not to donate eggs (ova) during the course of this study or 180 days after receiving their last dose of study drug
• •Male patients, even if surgically sterilized (i.e., status post-vasectomy), must:
• •* Agree to practice effective barrier contraception during the entire study treatment period and through 180 days after the last dose of study drug, or
• •* Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \[e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner\] and withdrawal are not acceptable methods of contraception. Female and male condoms should not be used together.)
• •* Agree not to donate sperm during the course of this study or within 180 days after receiving their last dose of study drug
• •Female of childbearing potential (FOCBP) must have a negative pregnancy test =\< 7 days prior to registration on study
• •Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
• •Patients must have the ability to swallow oral medication
• •Patients must be willing and able to complete study-required procedures